Fast relapse and high drop out rate of 48 weeks daily interferon monotherapy in HIV-infected patients with chronic hepatitis C

Raffaele Bruno, Paolo Sacchi, Massimo Puoti, Valentina Ciappina, Cristina Zocchetti, Enrico Brunetti, Elena Maffezzini, Anna Capelli, Savino F A Patruno, Antonello Malfitano, Gaetano Filice

Research output: Contribution to journalArticle

Abstract

Background: The standard of care for HCV Hepatitis is the combination of interferon (IFN) plus Ribavirin. In HIV patients the use of this combination therapy may induce drug interactions, and reduces the adherence to HAART. The aim of this study is to evaluate safety and efficacy of a 48 weeks daily dose IFN schedule. Methods: We evaluated 50 coinfected patients; alpha IFN 2a was administered at a dose of 3 MU daily. The baseline values were the following : CD4+ 515 cells/mmc (mean); HIV-RNA

Original languageEnglish
Article number17
JournalBMC Infectious Diseases
Volume2
DOIs
Publication statusPublished - Aug 28 2002

Fingerprint

Chronic Hepatitis C
Interferons
HIV
Recurrence
Ribavirin
Highly Active Antiretroviral Therapy
Standard of Care
Drug Interactions
Hepatitis
Appointments and Schedules
RNA
Safety
Therapeutics
interferon alfa-2a

Keywords

  • Coinfection
  • HCV
  • HIV
  • Interferon
  • Ribavirin

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Fast relapse and high drop out rate of 48 weeks daily interferon monotherapy in HIV-infected patients with chronic hepatitis C. / Bruno, Raffaele; Sacchi, Paolo; Puoti, Massimo; Ciappina, Valentina; Zocchetti, Cristina; Brunetti, Enrico; Maffezzini, Elena; Capelli, Anna; Patruno, Savino F A; Malfitano, Antonello; Filice, Gaetano.

In: BMC Infectious Diseases, Vol. 2, 17, 28.08.2002.

Research output: Contribution to journalArticle

@article{8cf945f8d8894b79ac39b86ad5e45b5b,
title = "Fast relapse and high drop out rate of 48 weeks daily interferon monotherapy in HIV-infected patients with chronic hepatitis C",
abstract = "Background: The standard of care for HCV Hepatitis is the combination of interferon (IFN) plus Ribavirin. In HIV patients the use of this combination therapy may induce drug interactions, and reduces the adherence to HAART. The aim of this study is to evaluate safety and efficacy of a 48 weeks daily dose IFN schedule. Methods: We evaluated 50 coinfected patients; alpha IFN 2a was administered at a dose of 3 MU daily. The baseline values were the following : CD4+ 515 cells/mmc (mean); HIV-RNA",
keywords = "Coinfection, HCV, HIV, Interferon, Ribavirin",
author = "Raffaele Bruno and Paolo Sacchi and Massimo Puoti and Valentina Ciappina and Cristina Zocchetti and Enrico Brunetti and Elena Maffezzini and Anna Capelli and Patruno, {Savino F A} and Antonello Malfitano and Gaetano Filice",
year = "2002",
month = "8",
day = "28",
doi = "10.1186/1471-2334-2-17",
language = "English",
volume = "2",
journal = "BMC Infectious Diseases",
issn = "1471-2334",
publisher = "BioMed Central Ltd.",

}

TY - JOUR

T1 - Fast relapse and high drop out rate of 48 weeks daily interferon monotherapy in HIV-infected patients with chronic hepatitis C

AU - Bruno, Raffaele

AU - Sacchi, Paolo

AU - Puoti, Massimo

AU - Ciappina, Valentina

AU - Zocchetti, Cristina

AU - Brunetti, Enrico

AU - Maffezzini, Elena

AU - Capelli, Anna

AU - Patruno, Savino F A

AU - Malfitano, Antonello

AU - Filice, Gaetano

PY - 2002/8/28

Y1 - 2002/8/28

N2 - Background: The standard of care for HCV Hepatitis is the combination of interferon (IFN) plus Ribavirin. In HIV patients the use of this combination therapy may induce drug interactions, and reduces the adherence to HAART. The aim of this study is to evaluate safety and efficacy of a 48 weeks daily dose IFN schedule. Methods: We evaluated 50 coinfected patients; alpha IFN 2a was administered at a dose of 3 MU daily. The baseline values were the following : CD4+ 515 cells/mmc (mean); HIV-RNA

AB - Background: The standard of care for HCV Hepatitis is the combination of interferon (IFN) plus Ribavirin. In HIV patients the use of this combination therapy may induce drug interactions, and reduces the adherence to HAART. The aim of this study is to evaluate safety and efficacy of a 48 weeks daily dose IFN schedule. Methods: We evaluated 50 coinfected patients; alpha IFN 2a was administered at a dose of 3 MU daily. The baseline values were the following : CD4+ 515 cells/mmc (mean); HIV-RNA

KW - Coinfection

KW - HCV

KW - HIV

KW - Interferon

KW - Ribavirin

UR - http://www.scopus.com/inward/record.url?scp=2342649056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342649056&partnerID=8YFLogxK

U2 - 10.1186/1471-2334-2-17

DO - 10.1186/1471-2334-2-17

M3 - Article

AN - SCOPUS:2342649056

VL - 2

JO - BMC Infectious Diseases

JF - BMC Infectious Diseases

SN - 1471-2334

M1 - 17

ER -